A New Way to Treat Alzheimer’s at Home

For patients and caregivers managing early Alzheimer’s disease, fewer trips to an infusion center could make treatment a little less burdensome. The FDA has now approved at-home subcutaneous lecanemab (Leqembi Iqlik), but at-home does not mean hands-off.

Highlighted in an August 2026 Medscape report by Brooks, patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease can now receive lecanemab through a once-weekly autoinjector at home. Data presented by Eisai and Biogen at AAIC 2026 showed the safety of at-home injections. This could eliminate many infusion-center visits and offer patients and caregivers greater flexibility.

The important catch: the necessary monitoring doesn’t go away with leaving the infusion chair. Patients still require clinician-supervised training, caregiver support, and regular MRI monitoring for ARIA (amyloid related imaging abnormalities). At-home treatment may make lecanemab more convenient, but it remains a treatment requiring careful medical oversight.

Learn More: https://media-us.eisai.com/2026-07-12-LEQEMBI-R-Subcutaneous-Autoinjector-Clinical-Data-Supports-Similar-Efficacy-and-Safety-to-IV-Formulation-in-Early-Alzheimers-Disease-Presented-at-the-Alzheimers-Association-International-Conference-R-AAIC-R-2026